Health
Partnership to develop head and neck cancer vaccine – Mirage News
Professor Christian Ottensmeier (centre)Cancer Research UK, the University of Southampton and Touchlight Genetics (a London based biotechnology company)…
Professor Christian Ottensmeier (centre)
Cancer Research UK, the University of Southampton and Touchlight Genetics (a London based biotechnology company) have announced a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
HNSCC is the UK’s eighth most common cancer, but treatment options are limited and around 4,000 of those affected in the UK die each year. Whilst exis…
-
Business15 hours agoTop brokers name 3 ASX shares to buy next week 16 November 2025
-
Business17 hours ago3 US dividend stocks that can boost an ASX retirement portfolio
-
Business14 hours agoASX 200 mining shares rip as lithium makes a comeback
-
General22 hours agoDemocratic Republic of Congo and M23 rebel group sign new roadmap to peace in Qatar